A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients - Trial NCT06361927
Access comprehensive clinical trial information for NCT06361927 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Timeline & Enrollment
Phase 2
May 15, 2024
Jul 01, 2025
Primary Outcome
ORR
Summary
This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for
 squamous NSCLC.
Data Source
ClinicalTrials.gov
NCT06361927
Non-Device Trial